Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Comparing the Survival Analysis of Two or More Groups

Comparing the Survival Analysis of Two or More Groups

Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Targeting macrophage ferritin heavy chain mitigates ferroptosis and lung injury in experimental acute respiratory distress syndrome.

Nature communications·2026

Same author

Lessons From GBM AGILE's Regorafenib Experience in Newly Diagnosed and Recurrent Glioblastoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Same author

Less Isn't Simple: Insights From Postmastectomy Radiotherapy Deintensification Trials.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Same author

SARC031: A Phase II Trial of Selumetinib and Sirolimus for Patients with Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumors (MPNST).

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Same author

Distinct Sarcoma Microenvironments Predict Benefit from Addition of Pembrolizumab to Preoperative Radiotherapy and Surgery in SU2C-SARC032.

medRxiv : the preprint server for health sciences·2025

Same author

Extracellular iron and the lung microbiome in smoking and COPD.

ERJ open research·2025

Same journal

Efficacy and Tolerability of Zenocutuzumab in Advanced <i>NRG1</i> Fusion-Positive Cholangiocarcinoma: Results From the eNRGy Phase II Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Same journal

Phase I/II Study of Sonrotoclax (BGB-11417) Monotherapy in Patients With Mantle Cell Lymphoma Previously Treated With Anti-CD20 Therapy and a Bruton Tyrosine Kinase Inhibitor.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Same journal

Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2026.3.2.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Same journal

Metabolic Modulation in Cancer Care: The Potential Role of Glucagon-Like Peptide-1 Receptor Agonists.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Same journal

Long-Term Follow-Up of JCOG1008, a Randomized Phase II/III Trial of Chemoradiotherapy Comparing 3-Weekly Cisplatin With Weekly Cisplatin in Postoperative Head and Neck Cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Same journal

First-Line Disitamab Vedotin, Tislelizumab, and S-1 in HER2-Overexpressing Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: A Single-Arm, Phase II Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Apr 3, 2026

Constructing and Visualizing Models using Mime-based Machine-learning Framework

Constructing and Visualizing Models using Mime-based Machine-learning Framework

Published on: July 22, 2025

Biomarker: Predictive or Prognostic?

Karla V Ballman¹

¹From Weill Cornell Medical College, New York, NY. kab2053@med.cornell.edu.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology

|September 23, 2015

Summary

This summary is machine-generated.

To prove a biomarker predicts treatment success, studies need biomarker data from treated and untreated patients, showing a significant treatment-biomarker interaction. Prognostic markers associate with outcomes irrespective of treatment.

More Related Videos

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

Predictive Immune Modeling of Solid Tumors

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

Related Experiment Videos

Last Updated: Apr 3, 2026

Constructing and Visualizing Models using Mime-based Machine-learning Framework

Constructing and Visualizing Models using Mime-based Machine-learning Framework

Published on: July 22, 2025

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

Predictive Immune Modeling of Solid Tumors

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

Area of Science:

Biostatistics
Clinical Trial Design
Biomarker Research

Background:

Biomarkers are crucial for personalized medicine, guiding treatment decisions.
Distinguishing predictive from prognostic biomarkers is essential for effective therapeutic strategies.

Purpose of the Study:

To outline the statistical requirements for demonstrating a biomarker's predictive value for treatment benefit.
To define the criteria for establishing a biomarker as purely prognostic.
To clarify the potential for biomarkers to possess both predictive and prognostic implications.

Main Methods:

Requires biomarker status for all patients, including treated and untreated groups, ideally within a randomized study.
Employs formal statistical tests for treatment-by-biomarker interactions to assess predictive value.
Examines the association between biomarker and outcome independent of treatment for prognostic assessment.

Main Results:

A significant treatment-by-biomarker interaction indicates predictive value.
A significant association between biomarker and outcome, irrespective of treatment, suggests a prognostic role.
Biomarkers can exhibit both predictive and prognostic characteristics.

Conclusions:

Rigorous study design and statistical analysis are necessary to validate biomarker roles in clinical decision-making.
Understanding the distinction between predictive and prognostic biomarkers optimizes therapeutic targeting and patient outcomes.